Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients

Fayette, Jérôme; Fontaine-Delaruelle, C.; Ambrun, A.; Daveau, Clémentine; Poupart, M.; Ramade, Antoine; Zrounba, Philippe; Neidhardt, Ève-Marie; Péron, Julien; Diallo, A K; Céruse, Philippe

doi:10.18632/oncotarget.8934

Cited by 32 publications

(17 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective study from J Fayette et al in France used the modified TPF regimen of docetaxel and cisplatin at 40 mg/2 on day 1 and a bolus of 5FU at 400 mg/m2, then 1000 mg/m2 on Day 1-2 every 2 weeks. The authors reported 10% of febrile neutropenia, 83% of overall response rate and 19% of complete response [22]. Notably, the regimen adopted by J Fayette et al was similar to that our study used, such as biweekly administration, and 48-h infusion of high-dose 5FU.…”

Section: Discussionsupporting

confidence: 74%

See 1 more Smart Citation

Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study

et al. 2020

View full text Add to dashboard Cite

Background: Phase 3 studies suggest that induction chemotherapy (ICT) of cisplatin and 5-fluorouracil plus docetaxel (TPF) is effective but toxic for patients with squamous-cell carcinoma of the head and neck (SCCHN). Dose-dense chemotherapy may yield favorable outcomes compared with standard-dose chemotherapy, yet the optimal induction regimen remains undefined. We assessed the efficacy and tolerability of biweekly dose-dense TPF ICT in patients with SCCHN. Methods: In this prospective phase II study, We enrolled patients with stage III/IV (AJCC 7th edition) unresectable squamous cell carcinoma of head and neck cancer. Patients received dose-dense TPF (ddTPF) with cisplatin and docetaxel 50 mg/m2 on day 1, leucovorin 250 mg/m2 on day1, followed by 48-h continuous infusion of 2500 mg/ m2 of 5-fluorouracil on day 1 and 2, every 2 weeks for 6 cycles followed by radiotherapy. The primary endpoint was the response rate (RR) after ICT. Results: Fifty-eight patients were enrolled from June 2014 to September 2015. Overall RR after ICT was 89.6% [complete response (CR), 31%; partial response (PR), 58.6%]. Grade 3/4 neutropenia, mucositis, and diarrhea incidences were 25.9, 1.7, and 1.7%, respectively. 94.8% of patients completed all treatment courses of ICT without dose reduction. The 3-year overall survival (OS) was 54.3% (95%CI: 39.7 to 66.8%) and progression-free survival (PFS) was 34.3% (95%CI: 22.0 to 46.9%). Multivariate analysis showed that CR after ICT is an independent prognostic factor for OS and PFS. Conclusions: Six cycles of ddTPF is an active, well-tolerated induction regimen for patients with SCCHN. The presence of CR after ICT predicted long-term survival.

show abstract

Section: Discussionsupporting

confidence: 74%

“…Toxicity is a major issue of ICT, with up to 6% toxic deaths and 11% of febrile neutropenia [ 4 , 20 ]. Some studies had tried to find fewer toxic regimens by reducing chemotherapy dose [ 21 , 22 ]. HM.…”

Section: Discussionmentioning

confidence: 99%

Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Patients were treated with TPF chemotherapy. The treatment procedure was as described previously 35 – 37 . Briefly, we performed three 21-day cycles of induction chemotherapy with docetaxel (75 mg/m 2 continuous i.v.…”

Section: Methodsmentioning

confidence: 99%

A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma

Fang

Huang

Yang

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. The five-year survival rate of HNSCC has not improved even with major technological advancements in surgery and chemotherapy. Currently, docetaxel, cisplatin, and 5-fluoruracil (TPF) treatment has been the most popular chemotherapy method for HNSCC; but only a small percentage of HNSCC patients exhibit a good response to TPF treatment. Unfortunately, at present, no reasonably effective prediction model exists to assist clinicians with patient treatment. For this reason, patients have no other alternative but to risk neoadjuvant chemotherapy in order to determine their response to TPF. In this study, we analyzed the gene expression profile in TPF-sensitive and non-sensitive patient samples. We identified a gene expression signature between these two groups. We further chose 10 genes and trained a support vector machine (SVM) model. This model has 88.3% sensitivity and 88.9% specificity to predict the response to TPF treatment in our patients. In addition, four more TPF responsive and four more TPF non-sensitive patient samples were used for further validation. This SVM model has been proven to achieve approximately 75.0% sensitivity and 100% specificity to predict TPF response in new patients. This suggests that our 10-genes SVM prediction model has the potential to assist clinicians to personalize treatment for HNSCC patients.

show abstract

“…[28][29][30] Other authors have limited its use to patients with good general condition including performance status 0 or 1, weight loss d" 10%, absence of severe comorbidities, < 70 years of age. 31 These data suggest that definitive CCRT should remain the standard of care while ICT should be reserved for patient population likely to receive greatest benefit from this strategy. 32,33 Conclusions The debate regarding the role of ICT in head and neck cancer is an open topic for discussion among the oncology fraternity for more than a decade now.…”

Section: Role Of Ict In Present Scenariomentioning

confidence: 96%

The changing landscape of induction chemotherapy in head and neck cancers

Negi¹,

Srivastava²,

Pa³

2019

International Journal of Health Research and Medico Legal Practice

View full text Add to dashboard Cite

In an attempt to improve the survival in locally advanced head and neck carcinomas, varying sequencing of treatment modalities namely surgery, radiation therapy and chemotherapy has been tried. Although concurrent chemoradiotherapy is the standard of care for these patients, induction chemotherapy is considered an effective alternative approach by head and neck oncologists worldwide. Induction chemotherapy continues to be actively pursued because of its potential to control locoregional disease, possible eradication of micrometastasis and organ preservation without jeopardizing overall survival. Inspite of the positive impact of docetaxel-based induction regimens, its direct comparison with the standard treatment failed to show superior results in terms of survival and completion of planned definitive radiation treatment. Several clinical trials have served to clarify the role of induction chemotherapy before definitive treatment in head and neck cancer, still the data remains controversial and warrants randomized controlled trials to ensure that most effective therapy is delivered with subsequent improvement in survival for these patients. This review summarizes key milestones in the evolution of induction chemotherapy in head and neck carcinoma.

show abstract

Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients

Cited by 32 publications

References 13 publications

Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study

Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study

A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma

The changing landscape of induction chemotherapy in head and neck cancers

Contact Info

Product

Resources

About